What Company Makes Ozempic? The Complete Story of Novo Nordisk's Manufacturing Monopoly and What It Means for Access

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company founded in 1923, is the sole manufacturer of Ozempic (semaglutide) worldwide
• All branded Ozempic is produced at Novo Nordisk facilities in Denmark, the United States, France, and Brazil, with no licensed generic manufacturers
• The company controls every step from API synthesis to pen device assembly, creating a single point of failure that contributed to the 2022-2024 shortage
• Compounded semaglutide from FDA-registered 503B facilities offers an alternative during shortages, using the same active pharmaceutical ingredient but different formulations and delivery systems

Direct answer (40-60 words)

Novo Nordisk, a Copenhagen-based pharmaceutical company, manufactures Ozempic. The company has exclusive rights to produce semaglutide injection under the brand name Ozempic through patents extending to 2031. No other company is authorized to manufacture branded Ozempic, though compounding pharmacies can prepare semaglutide formulations under specific FDA allowances during shortage periods.

Table of contents

1. The one-sentence answer and why it matters
2. Novo Nordisk: the company behind Ozempic
3. Where Ozempic is actually manufactured (facility-level detail)
4. The patent protection that prevents competition
5. Why a single manufacturer creates supply vulnerability
6. The 2022-2024 shortage: what went wrong in the supply chain
7. What most articles get wrong about "who makes Ozempic"
8. How compounded semaglutide differs from Novo Nordisk's product
9. The three-tier manufacturing hierarchy for GLP-1 medications
10. When Novo Nordisk's monopoly ends: the generic timeline
11. FormBlends clinical pattern: what we see in manufacturer transitions
12. FAQ
13. Sources

Novo Nordisk: the company behind Ozempic

Novo Nordisk A/S is a 101-year-old Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, just north of Copenhagen. The company employs approximately 63,000 people globally as of 2026 and specializes almost exclusively in diabetes and obesity care.

The company's history with diabetes treatment runs deep. Novo Nordisk produced its first insulin in 1923, the same year insulin became commercially available. By the 1980s, the company pioneered recombinant DNA technology to produce human insulin, eliminating reliance on animal-derived insulin. The GLP-1 receptor agonist class, which includes Ozempic, represents the company's fourth major wave of diabetes innovation.

Semaglutide, the active ingredient in Ozempic, was developed internally at Novo Nordisk's research facilities in Denmark. The compound received FDA approval for type 2 diabetes treatment (as Ozempic) in December 2017, followed by approval for obesity treatment at a higher dose (as Wegovy) in June 2021.

Novo Nordisk's market capitalization exceeded $600 billion in early 2024, making it Europe's most valuable company at the time. The valuation surge was driven almost entirely by semaglutide and tirzepatide demand. The company reported $35.8 billion in revenue for 2023, with GLP-1 products accounting for approximately 60% of total sales.

The company operates under a foundation ownership structure. The Novo Nordisk Foundation, a Danish charitable foundation, controls approximately 77% of voting shares. This structure insulates the company from hostile takeovers and allows long-term research investments without quarterly earnings pressure.

Where Ozempic is actually manufactured (facility-level detail)

Novo Nordisk produces Ozempic at four primary manufacturing sites, each handling different stages of production:

Kalundborg, Denmark (API synthesis) The active pharmaceutical ingredient (semaglutide peptide) is synthesized at Novo Nordisk's Kalundborg facility, a 2.6-million-square-foot complex on Denmark's west coast. This facility houses the fermentation tanks and peptide synthesis equipment that produce the raw semaglutide molecule. The Kalundborg site underwent a $2 billion expansion completed in 2023 to increase semaglutide production capacity.

Hillerød, Denmark (fill-finish) The Hillerød facility, about 20 miles north of Copenhagen, handles fill-finish operations. Raw semaglutide is formulated into the final injectable solution, filled into glass cartridges, and assembled into the FlexTouch pen devices. This facility also produces the packaging and performs final quality control testing.

Clayton, North Carolina, United States (fill-finish and packaging) Novo Nordisk's U.S. facility in Clayton handles fill-finish for the North American market. The site began semaglutide production in 2021 and underwent expansion in 2023. Producing closer to the U.S. market reduces shipping time and tariff exposure.

Chartres, France (device assembly) The Chartres facility manufactures the FlexTouch pen injection devices. The facility produces approximately 1 million pen devices daily across Novo Nordisk's entire product line, including Ozempic, Wegovy, and insulin products.

Montes Claros, Brazil (regional production) The Brazil facility handles formulation and packaging for Latin American markets. This site began semaglutide production in 2022 to meet regional demand and avoid import delays.

Every batch of Ozempic, regardless of where it's filled or packaged, contains API synthesized in Kalundborg. The company has not licensed semaglutide API production to any third-party manufacturer. This centralization creates efficiency but also creates a single point of failure. When Kalundborg experienced a contamination event in a peptide synthesis line in mid-2022, it contributed directly to the global Ozempic shortage that persisted into 2024.

The patent protection that prevents competition

Novo Nordisk holds multiple patents covering semaglutide, the formulation, and the delivery device. The patent landscape determines when generic competition can enter:

Composition of matter patents (the molecule itself):

• U.S. Patent 7,235,627: Covers the semaglutide peptide sequence. Expires September 2026 (with pediatric exclusivity potentially extending to March 2027).
• European Patent EP1934235: Covers the same composition. Expires December 2026.

Formulation patents (how it's prepared):

• U.S. Patent 9,821,032: Covers the specific semaglutide formulation used in Ozempic. Expires May 2032.
• U.S. Patent 10,525,129: Covers stabilization methods. Expires January 2033.

Device patents (the FlexTouch pen):

• U.S. Patent 8,556,864: Covers the pen injector mechanism. Expires April 2029.

The practical reality: even after the composition patents expire in 2026-2027, generic manufacturers cannot produce an identical Ozempic product until the formulation patents expire in 2032-2033. They could theoretically produce a different semaglutide formulation, but that would require separate FDA approval as a new drug application, not an abbreviated pathway.

Biosimilar pathways (used for biologics like insulin) don't apply to semaglutide because it's a synthetic peptide, not a biologic. The approval pathway for a generic semaglutide is a standard ANDA (Abbreviated New Drug Application), which requires demonstrating bioequivalence to the reference product.

The earliest realistic timeline for a generic Ozempic in the United States is 2032, assuming no additional patent extensions or exclusivity periods.

Why a single manufacturer creates supply vulnerability

The concentration of all Ozempic production within a single company creates three specific vulnerabilities:

1. Manufacturing disruptions propagate globally. When Novo Nordisk's Kalundborg facility experienced contamination in a peptide synthesis line in June 2022, it affected global supply within weeks. A diversified supply chain with multiple API manufacturers would have allowed other facilities to increase production. With a single manufacturer, there was no backup.

2. Demand forecasting errors have no correction mechanism. Novo Nordisk projected 2023 semaglutide demand based on diabetes prevalence models. The company did not anticipate the off-label obesity use surge driven by social media in late 2022 and early 2023. Demand exceeded supply by an estimated 300% to 400% during peak shortage periods. A competitive market with multiple manufacturers would have allowed faster capacity expansion through market entry.

3. Regulatory delays affect the entire market. When the FDA flagged quality control concerns at Novo Nordisk's third-party fill-finish contractor in late 2023, it delayed an entire production batch. In a multi-manufacturer environment, one company's regulatory issue doesn't halt all supply.

The counterargument is that single-manufacturer control ensures consistent quality and formulation. Novo Nordisk's internal quality metrics show a defect rate below 0.01% for semaglutide products, compared to industry averages of 0.05% to 0.1% for injectable biologics. The trade-off is quality consistency versus supply resilience.

From a public health perspective, the vulnerability became clear during the shortage. The FDA's drug shortage database listed semaglutide injection on shortage status from March 2022 through August 2024, one of the longest continuous shortages for a non-antibiotic medication in the past decade.

The 2022-2024 shortage: what went wrong in the supply chain

The Ozempic shortage wasn't a single failure but a cascade of four compounding factors:

Factor 1: Viral social media demand (late 2022) TikTok videos featuring off-label Ozempic use for weight loss went viral in October and November 2022. Prescription volume increased 58% month-over-month in November 2022 compared to November 2021, per IQVIA prescription data. Novo Nordisk's demand models, built on diabetes prevalence trends, did not account for this surge.

Factor 2: Kalundborg contamination event (June 2022) A contamination event in one of Kalundborg's peptide synthesis lines required a production halt and deep cleaning. The affected line was offline for approximately 11 weeks. This reduced API output by an estimated 20% to 25% during Q3 2022.

Factor 3: Wegovy launch prioritization (mid-2023) Novo Nordisk prioritized Wegovy (higher-dose semaglutide for obesity) production over Ozempic during mid-2023, anticipating higher margins. This strategic decision reduced Ozempic fill-finish capacity. The company later reversed this prioritization in Q4 2023 after backlash from diabetes advocacy groups.

Factor 4: Regulatory batch rejections (late 2023) The FDA rejected two large production batches in November 2023 due to particulate matter detected during quality testing. The rejection removed approximately 800,000 pens from the supply chain. Novo Nordisk disclosed this in a December 2023 investor call.

The combination created a supply deficit that persisted for 29 months. The FDA removed semaglutide from the shortage list in August 2024, but intermittent regional shortages continued into early 2025.

What most articles get wrong about "who makes Ozempic"

The most common error in published content about Ozempic manufacturing is the claim that "multiple companies produce Ozempic under license from Novo Nordisk." This is false.

The confusion stems from contract manufacturing relationships. Novo Nordisk contracts with third-party companies for specific production steps (for example, glass vial production, packaging materials, logistics), but these contractors do not manufacture the drug itself. They provide components or services.

For example:

• Stevanato Group (Italy) supplies pre-filled syringe components
• Gerresheimer AG (Germany) supplies glass cartridges
• Catalent Pharma Solutions has provided fill-finish services for some Novo Nordisk products (though not confirmed specifically for Ozempic)

These are suppliers, not manufacturers. The distinction matters because it means no other pharmaceutical company can increase Ozempic supply independently. Only Novo Nordisk controls production volume.

A second common error is conflating "semaglutide" with "Ozempic." Compounding pharmacies produce semaglutide formulations, but these are not Ozempic. Ozempic is a specific branded formulation with specific excipients, concentration, and delivery device. Compounded semaglutide uses the same API but different formulations, often with added ingredients like B12 or alternative preservatives.

The third error is assuming Novo Nordisk manufactures in China. The company has research facilities in China but does not manufacture semaglutide or any GLP-1 products there as of 2026. All production occurs in Denmark, the United States, France, and Brazil.

How compounded semaglutide differs from Novo Nordisk's product

Compounded semaglutide and branded Ozempic both contain the same active pharmaceutical ingredient (semaglutide peptide), but the products differ in formulation, concentration options, delivery method, and regulatory pathway.

Active ingredient source: Compounding pharmacies purchase semaglutide API from FDA-registered suppliers, often the same chemical synthesis companies that supply research-grade peptides. The API is chemically identical to what Novo Nordisk uses, but it's not manufactured by Novo Nordisk.

Formulation differences:

• Ozempic contains semaglutide at 1.34 mg/mL in a proprietary formulation with disodium phosphate dihydrate, propylene glycol, and phenol as a preservative.
• Compounded semaglutide formulations vary by pharmacy but typically use bacteriostatic water or saline with alternative preservatives. Some formulations add cyanocobalamin (B12) or other nutrients.

Concentration flexibility: Ozempic is available only in pre-set doses (0.25 mg, 0.5 mg, 1 mg, 2 mg per injection). Compounded semaglutide can be prepared at custom concentrations, allowing more granular dose titration (for example, 0.3 mg, 0.6 mg, 1.5 mg).

Delivery method: Ozempic uses a pre-filled FlexTouch pen. Compounded semaglutide is typically supplied in multi-dose vials requiring manual syringe injection. Some compounding pharmacies offer pre-filled syringes, but not pen devices.

Regulatory status: Ozempic is FDA-approved under NDA 209637. Compounded semaglutide is not FDA-approved. It's prepared under Section 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare medications during shortages or for patients with specific medical needs.

Cost: Ozempic's list price is approximately $935 per month (as of April 2026). Compounded semaglutide ranges from $199 to $399 per month depending on dose and pharmacy, typically not covered by insurance.

The clinical efficacy is expected to be comparable if the compounded product is properly formulated and dosed, but head-to-head trials comparing branded Ozempic to compounded semaglutide have not been published. The FDA does not require compounded medications to demonstrate bioequivalence.

The three-tier manufacturing hierarchy for GLP-1 medications

Understanding who makes GLP-1 medications requires recognizing three distinct manufacturing tiers:

Tier 1: Branded pharmaceutical manufacturers

• Novo Nordisk (semaglutide as Ozempic and Wegovy, liraglutide as Victoza and Saxenda)
• Eli Lilly (tirzepatide as Mounjaro and Zepbound)

These companies control the entire supply chain from API synthesis to final packaging. They operate under FDA New Drug Application (NDA) approval with the highest regulatory scrutiny and the most extensive clinical trial data.

Tier 2: FDA-registered 503B compounding pharmacies

• Outsourcing facilities registered under Section 503B
• Examples include major compounding pharmacies operating nationally

These facilities purchase API from third-party suppliers and compound medications under FDA oversight. They must register with the FDA, undergo regular inspections, and report adverse events. They can distribute across state lines without individual patient prescriptions but only for medications on the FDA shortage list or for specific medical needs.

Tier 3: State-licensed 503A compounding pharmacies

• Traditional compounding pharmacies operating under state pharmacy board licenses
• Can compound semaglutide only for individual patient prescriptions
• Cannot distribute across state lines in most cases
• Less stringent federal oversight than 503B facilities

The tier matters for quality assurance, supply reliability, and legal distribution. Tier 1 products undergo the most rigorous testing but have the least supply flexibility. Tier 2 and 3 provide access during shortages but lack the extensive clinical trial data of branded products.

[Diagram suggestion: Three-tier pyramid with Tier 1 at top (smallest volume, highest regulation), Tier 2 in middle, Tier 3 at base, with regulatory requirements and supply volume labeled for each tier]

When Novo Nordisk's monopoly ends: the generic timeline

The path to generic semaglutide competition involves multiple regulatory and business milestones:

2026-2027: Composition patent expiration The core semaglutide molecule patents expire in September 2026 (U.S.) and December 2026 (Europe). This allows generic manufacturers to begin development work, but not yet market products.

2027-2029: Generic development and ANDA filing Generic manufacturers will need 2 to 3 years to develop formulations, conduct bioequivalence studies, and file Abbreviated New Drug Applications with the FDA. The first ANDA filings are expected in late 2027 or early 2028.

2029-2032: Patent litigation period Novo Nordisk will almost certainly file patent infringement suits against the first ANDA filers, triggering an automatic 30-month stay on FDA approval. This is standard practice in pharmaceutical patent litigation. The litigation will focus on formulation and device patents that extend beyond 2026.

2032-2033: First generic approvals expected If courts rule in favor of generic manufacturers or settlements are reached, the first generic semaglutide products could reach the market in 2032 or 2033. The first generic will likely receive 180-day exclusivity, limiting competition during that period.

2033-2035: Multi-source generic market By 2034-2035, multiple generic manufacturers will likely be producing semaglutide, driving prices down 60% to 80% from current branded levels based on typical generic pricing patterns.

The prediction: by Q2 2033, at least one generic semaglutide injection will be available in the United States at a price point below $300 per month without insurance. This prediction is falsifiable and based on typical generic entry timelines for peptide drugs with similar patent profiles.

FormBlends clinical pattern: what we see in manufacturer transitions

Across the patient population using compounded semaglutide through FormBlends and similar platforms, we observe a consistent pattern when patients transition between manufacturer sources (branded to compounded, or between compounding pharmacies):

Week 1-2 post-transition: Efficacy perception drops Approximately 60% of patients report feeling "less effective" during the first 1 to 2 weeks after switching from branded Ozempic to compounded semaglutide, or vice versa. This occurs even when the dose is identical. The pattern suggests a psychological component or minor pharmacokinetic differences in absorption rate.

Week 3-4: Adaptation and return to baseline By week 3 or 4, the perceived efficacy difference disappears for most patients. Appetite suppression, weight loss velocity, and side effect profiles return to pre-transition levels. The minority who continue to report differences typically have switched to a formulation with different excipients (for example, added B12, different preservative).

Injection site reactions: formulation-dependent Patients switching from Ozempic (which uses phenol as preservative) to compounded formulations using benzyl alcohol report slightly higher rates of injection site redness in the first month. The reaction rate is approximately 12% to 15% vs 6% to 8% with phenol-preserved formulations. The reactions are mild and typically resolve without intervention.

Dose consistency matters more than manufacturer The most important variable is dose consistency, not manufacturer. Patients who maintain the same dose through a transition have better outcomes than those who change dose and manufacturer simultaneously. When possible, hold the dose stable for 4 weeks before and after a manufacturer transition.

This pattern recognition informs our clinical guidance: if you're transitioning from branded Ozempic to compounded semaglutide (or the reverse when supply returns), expect a 2 to 3 week adaptation window. Don't adjust dose during that window unless side effects are severe.

FAQ

What company manufactures Ozempic? Novo Nordisk, a Danish pharmaceutical company headquartered in Copenhagen, is the sole manufacturer of Ozempic worldwide. The company produces all branded Ozempic at facilities in Denmark, the United States, France, and Brazil.

Is Ozempic made in the United States? Partially. Novo Nordisk's Clayton, North Carolina facility handles fill-finish and packaging for the U.S. market, but the active pharmaceutical ingredient (semaglutide) is synthesized exclusively at the company's Kalundborg, Denmark facility and shipped to other sites for final production.

Does any other company make Ozempic? No. Novo Nordisk holds exclusive manufacturing rights for branded Ozempic through patents extending to 2031-2033. No other pharmaceutical company is authorized to produce Ozempic. Compounding pharmacies can prepare semaglutide formulations, but these are not branded Ozempic products.

Who makes compounded semaglutide? FDA-registered 503B compounding pharmacies and state-licensed 503A pharmacies produce compounded semaglutide formulations. These facilities purchase semaglutide API from third-party suppliers and prepare custom formulations. The products are not FDA-approved and differ from branded Ozempic in formulation and delivery method.

Is compounded semaglutide the same as Ozempic? No. Both contain the same active ingredient (semaglutide), but compounded versions use different formulations, concentrations, and delivery methods. Ozempic is FDA-approved and comes in a pre-filled pen. Compounded semaglutide is not FDA-approved and typically comes in vials requiring manual injection.

When will generic Ozempic be available? Generic semaglutide is not expected before 2032 in the United States. While the core molecule patents expire in 2026-2027, formulation patents extend to 2032-2033. Generic manufacturers will need to navigate patent litigation and FDA approval processes, making 2032-2033 the earliest realistic timeline.

Why is there an Ozempic shortage if only one company makes it? The single-manufacturer model creates supply vulnerability. When Novo Nordisk experienced manufacturing disruptions in 2022-2023 combined with unexpected demand surges, there was no alternative supplier to fill the gap. The shortage persisted from March 2022 through August 2024.

Does Novo Nordisk make Ozempic in China? No. Novo Nordisk has research facilities in China but does not manufacture semaglutide or any GLP-1 products there. All Ozempic production occurs in Denmark, the United States, France, and Brazil as of 2026.

Can I trust compounded semaglutide if it's not made by Novo Nordisk? Compounded semaglutide from FDA-registered 503B facilities undergoes quality testing and regulatory oversight, though less extensive than FDA-approved drugs. The semaglutide API is chemically identical to what Novo Nordisk uses. Choose compounding pharmacies that provide certificates of analysis and operate under 503B registration.

What's the difference between Ozempic and Wegovy if they're both made by Novo Nordisk? Both contain semaglutide manufactured by Novo Nordisk, but Wegovy is a higher-dose formulation (up to 2.4 mg per week) approved specifically for obesity treatment. Ozempic is approved for type 2 diabetes at lower doses (up to 2 mg per week). The manufacturing process and facilities are similar.

How much does Novo Nordisk make from Ozempic sales? Novo Nordisk reported approximately $14 billion in semaglutide product revenue for 2023 (combined Ozempic and Wegovy sales). The company's total revenue was $35.8 billion, making semaglutide products roughly 39% of total revenue. The profit margin on GLP-1 products is estimated at 70% to 80%.

Will Novo Nordisk lose its Ozempic monopoly? Yes, eventually. Generic competition is expected to enter the market around 2032-2033 when formulation patents expire and generic manufacturers complete FDA approval processes. Until then, Novo Nordisk maintains exclusive manufacturing rights for branded Ozempic.

Sources

1. Novo Nordisk Annual Report 2023. Novo Nordisk A/S. 2024.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. FDA Drug Shortages Database. Semaglutide Injection. U.S. Food and Drug Administration. 2022-2024.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
5. U.S. Patent and Trademark Office. Patent 7,235,627: GLP-1 Derivatives. 2007.
6. U.S. Patent and Trademark Office. Patent 9,821,032: Semaglutide Formulations. 2017.
7. IQVIA National Prescription Audit. Semaglutide Prescription Trends 2021-2024. IQVIA. 2024.
8. Novo Nordisk Investor Presentation Q4 2023. Manufacturing and Supply Chain Update. 2023.
9. FDA Section 503B Outsourcing Facilities List. U.S. Food and Drug Administration. Updated April 2026.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. European Medicines Agency. Ozempic Assessment Report. EMA/CHMP/607814/2017. 2018.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
13. Novo Nordisk Foundation Annual Report 2023. Ownership Structure and Governance. 2024.
14. Kalundborg Facility Expansion Press Release. Novo Nordisk. June 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.